Author

D. Smil

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 1 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1

Frequent Co-Authors

M. Vedadi· 3 shared C. Arrowsmith· 2 shared F. Li· 2 shared M. Schapira· 2 shared V. Santhakumar· 2 shared A. Allali-Hassani· 1 shared A. Bolotokova· 1 shared A. Dong· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

M. Vedadi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors

K. Devkota, M. Schapira, S. Perveen, A. Khalili Yazdi, F. Li, I. Chau, P. Ghiabi, T. Hajian, P. Loppnau, A. Bolotokova, K. J. Satchell, K. Wang, D. Li, J. Liu, D. Smil, , M. Vedadi

This paper identifies SAM competitive inhibitors of SARS-CoV-2 nsp14 methyltransferase and characterizes their mechanism, guiding the development of selective bi-substrate inhibitors.

bioRxiv · Feb 19, 2021Biochemistry

Rational Design and Synthesis of Selective PRMT4 Inhibitors: a New Chemotype for Development of Cancer Therapeutics

M. Sutherland, A. Li, A. Kaghad, D. Panagopoulos, F. Li, M. Szewczyk, D. Smil, C. Scholten, L. Bouche, T. Stellfeld, C. Arrowsmith, D. Barsyte, M. Vedadi, I. V. Hartung, H. Steuber, , V. Santhakumar

This study designs and synthesizes a new class of selective PRMT4 inhibitors with improved selectivity over other PRMT family members.

bioRxiv · Nov 17, 2020Pharmacology & Toxicology

Identification and Characterization of the First Fragment Hits for SETDB1 Tudor Domain

P. Mader, R. Mendoza-Sanchez, A. Iqbal, A. Dong, E. Dobrovetsky, V. Corless, S. Liew, S. Houliston, R. Ferreira De Freitas, D. Smil, C. Dela Sena, S. Kennedy, D. Diaz, H. Wu, L. Dombrovski, , C. Arrowsmith

The paper identifies small molecule fragments that bind to the tudor domain of SETDB1 and describes their binding modes and biophysical properties.

Bioorganic & Medicinal Chemistry · Sep 1, 2019Peer-reviewedPharmacology & Toxicology